AXSM Axsome Therapeutics Inc.

3.4
0  0%
Previous Close 3.4
Open 3.45
Price To Book 6.94
Market Cap 87330673
Shares 25,685,492
Volume 90,970
Short Ratio 5.73
Av. Daily Volume 198,785

SEC filingsSee all SEC filings

  1. 8-K - Current report 18881572
  2. 8-K - Current report 18880064
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18815404
  4. 8-K - Current report 18812920
  5. DEF 14A - Other definitive proxy statements 18785989

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 commencement of enrollment announced April 23, 2018. Top-line data due 2019.
AXS-05
Smoking cessation
Phase 2/3 initiation announced July 17, 2017. Interim analysis due 2H 2018. Interim effiacy analysis due 2019 with top-line data due 2H 2019 – 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Interim analysis April 26, 2018 recommended trial to continue. Interim efficacy analysis due 2H 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes
Phase 3 trial planned for 2018.
AXS-07
Migraine
Phase 2 trial initiation announced June 5, 2018. Data due 2H 2018.
AXS-05 ASCEND
Major Depressive Disorder

Latest News

  1. Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
  2. Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
  3. Axsome Therapeutics to Present at the 2018 BIO International Convention
  4. Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?
  5. Axsome: 1Q Earnings Snapshot
  6. Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
  7. Axsome Therapeutics, Inc. to Host Earnings Call
  8. Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
  9. Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
  10. Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
  11. Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation
  12. Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
  13. Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
  14. Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
  15. Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
  16. Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day
  17. Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
  18. Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference

SEC Filings

  1. 8-K - Current report 18881572
  2. 8-K - Current report 18880064
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18815404
  4. 8-K - Current report 18812920
  5. DEF 14A - Other definitive proxy statements 18785989
  6. 8-K - Current report 18776106
  7. 8-K - Current report 18767916
  8. 8-K - Current report 18762471
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18737010
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 18673824